Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

June 17, 2024

https://www.globenewswire.com/news-release/2024/06/17/2899518/0/en/Arvinas-Announces-Promotions-of-Ian-Taylor-Ph-D-to-President-of-Research-and-Development-and-Angela-Cacace-Ph-D-to-Chief-Scientific-Officer.html

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.